Personalis Inc. Common Stock (PSNL)

FairStock Score: 30/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a disciplined investor, I want a business that earns more than it spends and has some durable advantage. Personalis operates in cancer genomics with NeXT Personal and ImmunoID NeXT, a promising area, but the filed numbers do not yet show a self-sustaining enterprise. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $22.4M, up from $17.2M in fiscal Q2 2025, the quarter ended 2025-06-30, yet net loss widened to $31.7M from $20.1M. For FY2025, the year ended 2025-12-31, revenue was $69.6M and net loss was $81.3M; FY2024 revenue was $84.6M with the same $81.3M loss; FY2023 revenue was $73.5M with a $108.3M loss. That is not a compounding earnings machine. FairStock’s calculations at the 2026-10-13 close of $15.85 show a P/E of -14.54, P/B of 7.17, ROE of -50.32%, ROCE of -25.03%, and FCF yield of -6.0%, with trailing free cash flow of -$101.0M. The Piotroski F-Score is 3/9, the Altman Z-Score is 10.57, and the FairStock Score is 30/100; debt is modest with D/E of 0.16, but cash burn is the central fact. A $1.7B market cap against FY2025 revenue of $69.6M requires extraordinary future success. The Lynch screen rightly finds no category because losses have persisted four years. I would call this a speculative diagnostics story, not a value investment with a margin of safety.

In plain English: Personalis makes advanced cancer tests that look for tiny amounts of cancer in the body and help guide treatment. Sales are rising, but the company loses much more money than it earns and has been unprofitable for years, so the business looks financially weak. At $15.85, the stock looks expensive compared with those losses and its assets, even though it is below its 52-week high.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer